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ABSTRACT Celiac disease (CD) is an immune-mediated
enteropathy triggered by the ingestion of gluten-containing
grains that affects ~1% of the white ethnic population. In the
last decades, a rise in prevalence of CD has been observed that
cannot be fully explained by improved diagnostics. Genetic
predisposition greatly influences the susceptibility of individuals
towards CD, though environmental factors also play a role.
With no pharmacological treatments available, the only option
to keep CD in remission is a strict and permanent exclusion of
dietary gluten. Such a gluten-free diet is difficult to maintain
because of gluten’s omnipresence in food (e.g., additive in
processed food). The development of adjuvant therapies which
would permit the intake of small amounts of gluten would be
desirable to improve the quality of life of patients on a gluten-
free diet. Such therapies include gluten-degrading enzymes,
polymeric binders, desensitizing vaccines, anti-inflammatory
drugs, transglutaminase 2 inhibitors, and HLA-DQ2 blockers.
However, many of these approaches pose pharmaceutical
challenges with respect to drug formulation and stability, or
application route and dosing interval. This perspective article
discusses how pharmaceutical scientists may deal with these
challenges and contribute to the implementation of novel ther-
apeutic options for patients with CD.
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ABBREVIATIONS
APC antigen-presenting cell
CD celiac disease
GFD gluten-free diet
GI gastrointestinal
HLA human leukocyte antigen
IEL intraepithelial lymphocyte
IgA immunoglobulin A
IL-15 interleukin-15
P(HEMA-co-SS) poly(hydroxyethylmethacrylate-
co-styrene sulfonate)
PEP prolyl endopeptidase
TfR transferrin receptor
TG2 transglutaminase 2
INTRODUCTION
Celiac disease (CD) is defined as “a chronic small intes-
tinal immune-mediated enteropathy precipitated by ex-
posure to dietary gluten in genetically predisposed
individuals” (1). Nonetheless, CD is a systemic disease
with a wide variety of clinical symptoms (2,3). A recent
study based on serologic testing found a prevalence of
up to 1% among the white ethnic population (4). CD
prevalence has been on the rise for many decades, with
a five-fold increase reported in the United States since
the 1970s. Improved diagnostic methods do not fully
account for this increase (5). In some populations, such
as in type I diabetics (at least 10%), the prevalence is
even higher (6). As CD is seen as a growing and serious
health problem, developing therapeutic strategies against
CD may have a profound scientific and clinical impact.
In this perspective article, the pathogenesis and
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diagnostic methods for CD are briefly reviewed and the
pharmaceutical challenges associated with future thera-
peutic options are critically discussed.
PATHOGENESIS OF CD
CD is triggered by gluten, which is a mixture of digestion-
resistant proteins found in wheat, barley, and rye (7). Gluten
is a very common nutritional component in Western
countries, with an average intake of approximately 20 g
per day per person (8). It consists of polymeric (glutenins)
and monomeric (gliadins) protein fractions that possess a
high immunogenic (i.e., activation of adaptive immunity)
or toxic (i.e., activation of innate immunity) potential in
genetically predisposed individuals (8,9). Some gliadin seg-
ments are highly stable towards degradation by intraluminal
proteases and intestinal brush-border membrane enzymes
due to their high proline and glutamine content (10). Con-
sequently, large peptide fragments of gluten remain intact in
the duodenal lumen, and subsequently cross the epithelium
para- and transcellularly to reach the lamina propria (11).
Paracellular permeability is linked to compromised tight
junction integrity where gluten is thought to stimulate the
release of the intestinal peptide zonulin, an agent that re-
versibly opens tight junctions (12). The transcellular path-
way involves secretory immunoglobulins A (IgA), which
bind gliadin peptides, and are subsequently internalized by
the transferrin receptor (TfR, CD71) of epithelial cells (13).
The peptides are then deamidated by tissue transglutami-
nase 2 (TG2), an enzyme catalyzing the hydrolysis of gluta-
mine to glutamic acid residues (14). TG2-mediated
deamidation introduces negative charges into the
glutamine-rich gliadin peptides such that their avidity to
human leukocyte antigen (HLA)-subtypes DQ2 and DQ8
of antigen-presenting cells (APCs) is increased (15). APCs
present the antigen to naïve gluten-reactive CD4+ T cells
and activate them. These T lymphocytes secrete proinflam-
matory cytokines (e.g., INFγ, TNFα) and induce the char-
acteristic antibody response by activation of gluten- and
TG2-reactive B cells (8,16). The role of anti-TG2 autoanti-
bodies in the pathogenesis of CD is not well understood.
Pathogenic effects on enterocytes and on the intestinal epi-
thelial barrier were described but remain of uncertain clin-
ical relevance (16). However, immunodeposits of
autoantibodies against TG2 and the TG-isoform of the
epidermis TG3 (due to cross-reactivity or epitope spreading)
were found in skin lesions of an extraintestinal manifestation
of CD, dermatitis herpetiformis (16). The innate immunity
is also implicated in the pathogenesis of CD (17). Enter-
ocytes, dendritic cells, and macrophages secrete proinflam-
matory cytokines such as interleukin-15 (IL-15), which
mediate abnormal cellular cytotoxicity by intraepithelial
lymphocytes (IEL). Activation of IELs, and in addition se-
cretion of matrix metalloproteases by fibroblasts and lamina
propria mononuclear cells result in histologically detectable
lesions of the intestinal epithelium (8,16,18). Moreover, IL-
15 in combination with retinoic acid prevents the generation
of regulatory T cells (19).
SYMPTOMS AND DIAGNOSTICS
CD is a systemic disease associated with symptoms of wide
variety and intensity (1). Symptomatic CD patients present
with intestinal and/or extraintestinal symptoms (anemia,
osteoporosis, dermatitis herpetiformis) (1). Intestinal symp-
toms are further classified in typical malabsorption signs
(e.g., weight loss, diarrhea, steatorrhoea) and abdominal
symptoms without malabsorption (e.g., abdominal pain,
constipation, vomiting) (1,20). Asymptomatic forms do not
show clinical manifestations even though they are serologi-
cally and histologically positive for CD (1,16). Potential CD
cases exhibit a normal small intestinal histology but they are
serologically positive for CD and at an elevated risk to
develop the disease (1). Following the celiac iceberg model,
it is assumed that typical CD cases are less prevalent than
asymptomatic and potential forms (21). As a result, the ratio
of diagnosed to undiagnosed CD cases is low, ca. 0.2 (4).
Gluten also elicits adverse effects separate from CD such as
IgE-mediated wheat allergy or non-celiac gluten sensitivity, a
highly prevalent (up to 6%) condition in which gluten intake
is associated with an increase in markers of the innate im-
mune response and symptomatic manifestations (e.g., ab-
dominal pain, behavioral changes, bone or joint pain and
weight loss) even though CD is diagnostically ruled out
(20,22). Genetic factors contribute to the risk of develop-
ing CD. More than 90% of CD patients express HLA-
DQ2; the others express HLA-DQ8 (8). In view of the
high frequency of HLA-DQ2 in controls (about 30%),
HLA-DQ2 or DQ8 genes are necessary but not sufficient
for the development of the disease (23,24). The HLA-
and non-HLA-genes identified to modulate the probabil-
ity of developing CD contribute around 50% to the
disease risk (16). Moreover, monozygotic twins have a
concordance rate of 75% to develop CD (16). Both
factors support the influence of environmental factors
involved in CD. A detailed discussion of the genetic
aspects of CD is available in reference (25).
Tests to detect CD-specific antibodies are widespread
because they are easy-to-use and non-invasive. They include
detection of IgA-type anti-TG2, anti-deamidated gliadin
and anti-endomysial antibodies (26). According to the Amer-
ican Gastroenterological Association, a diagnosis of CD relies on a
positive antibody test and on a positive small-bowel mucosal
biopsy upon gastrointestinal (GI) endoscopy (Medical
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Position Statement 2006). However, the diagnosis of CD
without biopsy is permitted in certain cases by the new
guidelines of the European Society for Paediatric Gastroenterology
Hepatology and Nutrition (27). Histologic characteristics of ac-
tive CD include inflammation of the intestinal mucosa,
increased IEL density, crypt hyperplasia, and in most cases
villous atrophy (26). As HLA typing has a negative predic-
tive value of almost 100%, it is a cost-effective alternative to
exclude the diagnosis of CD in potential and asymptomatic
cases (26).
PREVENTION AND TREATMENT
With no effective pharmacological treatments available,
preventive measures based on a better understanding of
disease-influencing environmental factors may help reduce
the incidence of CD. However, clear evidence on how
prevention methods could reduce the prevalence of CD is
lacking and clinical trials are still ongoing. For a detailed
description of the role of environmental factors and preven-
tive measures, the reader is referred to reference (8). After
diagnosis of CD, a complete and life-long exclusion of
gluten from the diet has to be implemented to keep CD in
remission. Although a gluten-free diet (GFD) is beneficial
(e.g., due to symptomatic relief), it is expensive and difficult
to maintain, especially when eating out or travelling and in
situations of increased social pressure (8). Approximately
one third of CD patients do not fully adhere to a GFD
due to social or educational reasons (28), resulting in in-
creased morbidity and mortality (29). Fifty percent of
patients that fully adhere to a GFD do not achieve histolog-
ical remission because of continued gluten-intake of around
5–50 mg of gluten per day (30). The reasons for this uncon-
scious exposure include inadvertent dietary consumption
due to gluten-contamination or presence of gluten as an
additive in processed food. In addition, rules on “gluten-
free” labeling of foodstuff varies between countries (8). The
production of wheat devoid of immunogenic peptidic sequences
could ease dietary restrictions in the future. Such wheat can be
generated by fermentation or genetic modification. Problems
associated with this approach include reduced baking quality,
gluten-contamination, and continued immune response to rye
and barley (Fig. 1) (8,30,31). Several pharmacological adjuvant
therapies which would allow safe ingestion of small amounts of
gluten are currently being explored (Table I). They are
discussed in more detail below.
Desensitization
Repeated administration of select immunogenic gliadin
peptides was shown to inhibit T cell proliferation and ex-
pression of proinflammatory cytokines (IL-2, IFNγ) in a
transgenic HLA-DQ2 mouse model (32). Nexvax2®
(ImmuSanT) is a desensitizing vaccine consisting of three
immunogenic gluten peptides from wheat, barley and rye,
developed as an immunotherapeutic and prophylactic agent
to restore gluten tolerance (33). In a phase I clinical trial
(NCT00879749), Nexvax2® was weekly administered to
HLA-DQ2-positive patients on a strictly GFD by intrader-
mal injection for 3 weeks. Detection of INFγ-producing
Nexvax2®-specific T cells in several subjects confirmed the
bioactivity of the vaccine (33). Even though vaccination
against CD is the preferred option for CD patients when
asked to rank alternatives to GFD (31), the periodicity of
Nexvax2® injections may have a negative impact on com-
pliance. Therefore, sustained release formulations com-
posed of biodegradable polymers (e.g., aliphatic polyesters)
such as microspheres or in situ forming implants could be
explored in the future as alternatives to periodic injections.
In phase Ib, intradermal injections with microneedles (e.g.,
BD Soluvia™, BD) are planned. Further challenges are a
potential immune system activation with a disease flare in
response to the vaccine (31), and the restriction to patients
with HLA-DQ2. Another investigated means of desensitiz-
ing patients is hookworm-infection (34). CD patients were
cutaneously inoculated twice with larvae of the hookworm
Necator americanus in a phase Ib/IIa trial (NCT00671138),
and subsequently underwent a wheat challenge for 5 days
(16 g of gluten/day). No significant differences between
infected and non-infected patients were seen with respect
to histological, clinical, or inflammation-related parameters
(34). Further analysis of the biopsy specimens, however,
indicated that hookworm-infection lowered the production
of proinflammatory cytokines (IL-17A, IFNγ) but did not
influence the response of duodenal memory T cells towards
a gliadin peptide (35). A challenge to the hookworm-
approach is establishing adequate amounts of applied hook-
worm larvae as heavy hookworm infections can cause seri-
ous adverse effects and underdosing dilutes the
desensitization effect (34). Purification, formulation, and
storage of the hookworm larvae may also be pharmaceuti-
cally challenging and could have an influence on adverse
reactions and compliance. Due to both, pharmaceutical
challenges and lack of clinical benefit for CD patients, the
efficiency of this approach remains debatable.
Polymeric Binders
Polymeric binders are being evaluated as a means to seques-
ter gluten in the GI tract (36). Poly(hydroxyethyl methacry-
late-co-styrene sulfonate) (P(HEMA-co-SS), BL-7010,
BioLineRx) was shown to complex gliadin and decrease
the production of immunostimulatory peptides in digestive
fluids (37,38). In a mouse model of gluten sensitivity, the
polymer diminished the mucosal and systemic response to
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an oral gluten-challenge. In addition, the polymer was safe
and the systemic exposure was found to be minimal in
rodents (38). In ex vivo experiments with biopsy specimens
from CD patients, secretion of the proinflammatory
cytokine TNFα was lowered upon gliadin exposure in the
presence of P(HEMA-co-SS) (38). An important advantage
of the polymeric binder P(HEMA-co-SS) is its ability to
sequester gluten under acidic and neutral conditions (i.e.,
Fig. 1 Many therapeutic strategies are being explored in CD (in blue). Pharmaceutical scientists face interesting challenges in overcoming shortcomings with
potentially negative effects on compliance and therapeutic benefit (in red).
Table I Adjuvant Therapies Under Investigation for CD. The Clinical Trials from this Table are Listed on clinicaltrials.gov (Status as of November 2012)
Therapeutic strategy Compound Progress Reference
Desensitization Nexvax2®-vaccine Phase I (33)
Necator americanus-inoculation Phase II (34)
Oral enzyme supplementation AN-PEP Phase II (43)
ALV003 Phase II (45)
Polymeric binders P(HEMA-co-SS) (BL-7010) Preclinical (38)
Modulators of paracellular permeability Larazotide acetate (AT-1001) Phase II (52)
TG2-inhibitors R281, ZED1098, ZED1219, ZED1227 Preclinical (56,58)
HLA-blockers Several compounds Discovery (60)
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in the stomach and the small intestine) (37). The binding of
the polymer to important nutrients has been pointed out as
a potential drawback of this approach. However, since the
treatment is to be used only occasionally, nutritional defi-
ciencies should not be of concern. The sequestration of
enough gluten to achieve a clinical response will remain
the most important challenge in the forthcoming clinical
trials.
Oral Enzyme Supplementation
One of the most studied therapeutic options for CD is the
oral administration of gluten-degrading enzymes (“glute-
nases”). Mixtures of germinating wheat proteases and puri-
fied prolyl endopeptidases (PEPs) have been reported to
hydrolyse proline-rich gluten and to reduce their T cell
toxicity in vitro (39,40). PEPs from different bacterial (FM,
MX, and SC PEP from Flavobacterium meningosepticum, Myx-
ococcus xanthus, and Sphingomonas capsulata, respectively) and
fungal species (AN PEP from Aspergillus niger) have been
extensively studied (41,42). In a pilot clinical trial
(NCT00810654), AN PEP (DSM Food Specialties) or
placebo-containing jam was administered to CD patients
with a breakfast comprising 7 g of gluten twice in 2 weeks.
No significant histopathological or serological differences
between AN PEP and placebo were observed as too few
patients in the control group showed a disease flare (43). AN
PEP is particularly active to degrade gluten in the stomach
and is being considered as potential food supplement.
ALV003 (Alvine Pharmaceuticals) is a mixture of two pro-
teases, i.e. SC PEP and EP-B2. The latter is the self-
activating isoform 2 of cysteine endoprotease B from germi-
nated barley seeds, a glutamine-specific endoprotease par-
ticularly resistant to low pH and pepsin (44). In a phase I
clinical trial (NCT00669825), ALV003 was applied as a
powder dissolved in water via a nasogastric tube subsequent
to a gluten-containing meal (1 g of gluten). Apart from being
well tolerated, three hundred mg of ALV003 degraded 80%
of administered gluten, which was significantly different
from placebo (44). A phase IIa study showed the capacity
of nine hundred mg of ALV003 to protect against small-
intestinal mucosal injury and to reduce IEL density com-
pared to placebo after a 6 weeks daily gluten challenge (2 g
gluten/day) (45). Unfortunately, this trial was underpow-
ered to achieve significant differences in serology or symp-
toms (45). Other clinical trials are ongoing, and ALV003
was subsequently granted Fast Track designation from the
FDA. A major challenge of the glutenase approach is the
susceptibility of PEPs to the harsh conditions of the GI tract
(46). In rats, the activity of some PEPs was shown to be
strongly dependent upon the stomach pH (47) such that
food composition will have an influence on therapeutic
benefit. To circumvent this problem, MX PEP has been
formulated with enteric capsules (48). However, ideally the
degradation of gluten in the stomach should be as complete
as possible to suppress an immune response in the proximal
small intestine. Furthermore, the time and point of release
of PEPs from enteric capsules fluctuates in relation to food
amount and content as well as intestinal pH. To increase the
stability of gluten-degrading enzymes in the stomach and
the small intestine, protein-engineering approaches and co-
valent modification of PEPs with polymers are being inves-
tigated (49,50). These strategies may be viewed as costly but
they represent very interesting research challenges for the
pharmaceutical scientist as findings stemming from this re-
search could be applied to other GI diseases and oral en-
zyme therapeutics.
Modulator of Paracellular Permeability
The enhanced permeability of the intestinal mucosa in active
CD is partly caused by gliadin-mediated opening of tight
junctions (12). Larazotide acetate (AT-1001, Alba Pharma-
ceuticals) is a peptidic tight junction regulator that was shown
to preserve tight junction structure of the intestinal epithelium
both in vitro and in gliadin-sensitized mice upon gliadin-
administration (51). In a recently reported phase IIa study
(NCT00362856), larazotide acetate was applied in capsules
before a gluten-containing meal thrice per day for 14 days
(2.4 g of gluten/day in total) (52). No statistical significance
between larazotide acetate and placebo was achieved for the
primary outcome measure for efficacy (lactulose-to-mannitol
ratio to assess intestinal permeability) (52). However, symptom
severity determined with a questionnaire to quantify GI symp-
toms was significantly lower for the treatment group after
gluten challenge (52). Finding appropriate markers for intesti-
nal permeability is challenging. The reliability of lactulose as a
marker for increased paracellular leakage of gliadins was con-
tested with regard to the molecular weight of lactulose
(342 Da) compared to immunogenic gliadin peptides such as
p31-49 and 33mer (2,245 and 3,900 Da, respectively) (53). A
fluorescently-labeled gliadin fragment may be of higher rele-
vance (54). One potential limitation of paracellular blockade is
the remaining systemic access of gliadin via the transcellular
route (IgA-gliadin-conjugates bind the TfR and are transcy-
tosed) (13). Competitive inhibition of gliadin-binding to IgA or
IgA-binding to TfR could be achieved with non-immunogenic
peptides and proteins but their susceptibility to degradation in
the GI tract should be verified. To increase their resistance
against proteolysis, the introduction of D-amino acids or cy-
clization represent interesting avenues to explore.
TG2-Inhibitors and HLA-Blockers
Inhibition of TG2 abolishes TG2-mediated deamidation of
immunogenic gliadin peptides and thus decreases their
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avidity to HLA-DQ2 and DQ8. Several reversible and irre-
versible TG2-inhibitors have been proposed (55). The TG2-
inhibitor R281 has been tested in vitro and ex vivo and showed
lowered gliadin-induced toxicity (56). The safety and efficacy of
TG2-inhibitors have not been evaluated in humans. Adverse
effects due to TG2’s ubiquity and sequence-similarities to the
active site of other human transglutaminases are possible (15).
In TG2-knockout mice, macrophage-mediated phagocytosis of
apoptotic cells was disturbed leading to splenomegaly, autoim-
munity and immune complex glomerulonephritis (57). Three
highly soluble and GI-stable peptidomimetic TG2-inhibitors
(ZED1098, ZED1219 and ZED1227, Zedira) with very high
selectivity for TG2 were recently developed (58). Their perme-
ation across the GI mucosa will need to be carefully assessed to
make sure that their concentration in the lamina propria is
sufficient. A challenge to TG2-inhibitors is the development
of an oral delivery system for maximal GI exposure of the drug.
The inhibitor should cross the GI mucosa in sufficiently high
concentrations while systemic exposure should be as low as
possible. TG2-inhibitors might prove more useful in combina-
tion therapy since some gluten peptides are immunogenic
without TG2-mediated deamidation (59). Another approach
consists in blocking HLA-DQ2 and DQ8 with high avidity
peptidic ligands in order to inhibit the presentation of immu-
nogenic gluten-derived peptides by APCs (60). Challenging
aspects of the HLA-blocking approach are the peptidic nature
of the competitive HLA-blockers, which makes them prone to
degradation in the GI tract, the need for high concentration
and avidity, as well as possible interference with presentation of
peptides from pathogens on HLA-DQ2 and DQ8 (8).
Anti-Inflammatory Therapy
Modulation of proinflammatory pathways can be achieved
with corticosteroids and biologics. Budesonide, a glucocorticoid
with low oral bioavailability, was clinically beneficial for refrac-
tory (i.e., non-responsive to a GFD) and non-refractory CD
(61,62). Its use in CDwould require a formulation targeting the
proximal small intestine given that budesonide is currently
mostly used for inflammatory bowel diseases affecting the ileum
and colon (24). Several proinflammatory cytokines and
lymphocyte-recruiting chemokines (e.g., TNFα, IFNγ, IL-15,
CCL25, CXCL10) were recently identified to be particularly
relevant in CD (31). For some of these targets, biological drugs
are either being developed or are already on the market but for
other indications. For example, a human IgG1 anti-IL-15
monoclonal antibody (AMG-714, Amgen) was evaluated in
patients with rheumatoid arthritis (63), but was discontinued
for this indication due to a disappointing phase II study (64).
Infliximab (Remicade®, Janssen Biotech), a monoclonal anti-
body blocking TNFα used in RA and Crohn’s disease, had
positive effects on a patient with refractory CD after failure of
corticosteroid therapy (65). However, clinical trials with
outcome measures designed for CD do not exist for most
anti-inflammatory agents. Severe adverse effects and high costs
(66) may disqualify TNFα blockers for non-refractory CD, as a
GFD is a relatively safe and inexpensive alternative (8). More-
over, periodic administration of biological drugs by trained
personnel is expensive andmight be addressed by subcutaneous
self-injection devices or by developing compounds with long
circulation times (e.g., PEGylation technologies) (67).
CONCLUSION
CD is an immune-mediated enteropathy affecting 1% of
the population and rising in prevalence. Because of grow-
ing awareness of gluten-related disorders, avoidance of
dietary gluten is increasingly common, even in non-
celiacs. With no pharmacologic treatments currently
available, formulation scientists may have a pivotal role
to play in the development of clinically viable pharma-
cological options. Specific delivery systems are required
to reduce adverse effects and to transport drugs to their
site of action. Improvements in the formulations of
peptide- and protein-based drugs are needed to enhance
their stability and activity, and will therefore be highly
instrumental in ameliorating treatment strategies for CD.
Pharmaceutical scientists can make significant contribu-
tions to reduce the burden on CD patients and make a
significant impact on their quality of life.
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